LETTER TO THE EDITOR
Year : 2013  |  Volume : 8  |  Issue : 1  |  Page : 81-82

Acute encephalopathy following the use of aluminum hydroxide in a boy affected with chronic kidney disease

Majid Malaki
Nephrology Department, Pediatric Health Research Center, Tabriz Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

Date of Web Publication

6-May-2013

Correspondence Address:
Majid Malaki
(Pediatric Nephrologist), Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz
Iran

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/1817-1745.111439

How to cite this article: Malaki M. Acute encephalopathy following the use of aluminum hydroxide in a boy affected with chronic kidney disease. J Pediatr Neurosci 2013;8:81-2

How to cite this URL: Malaki M. Acute encephalopathy following the use of aluminum hydroxide in a boy affected with chronic kidney disease. J Pediatr Neurosci [serial online] 2013 [cited 2022 Aug 8];8:81-2. Available from: https://www.pediatricneurosciences.com/text.asp?2013/8/1/81/111439

Dear Sir,

Berlyn first described aluminum toxicity due to using aluminum hydroxide for peptic ulcer. After that physicians recognized its phosphate absorption properties caused serum phosphor decline and calcium level increase. All these effects introduced aluminum as a principle drug for uremic patients by the early 70s. Berlyn found aluminum deleterious effects without measuring of serum aluminum level. ^[1] Acute aluminum toxicity has been less described although children with hyperparathyroidism and preexisting developmental delaying are more prone to aluminum toxicity. ^[2],[3]

Acute aluminum neurotoxicity is related to accumulation of aluminum in the gray matter of the brain. ^[4] Aluminum toxicity in acute form can present from days to weeks, and chronic forms happen insidiously over a period of months to years. ^{[5],[6],[7],[8]} A wide range of complaints, mainly in cognition and speech disorders, lead to motor seizure, coma, and death. ^[9],[10] The reports mainly described acute aluminum toxicity in adults, ^[11] while in this case report, we present an 18-month-old boy with secondary hyperparathyroidism due to CRF, who developed acute encephalopathy following short-term aluminum hydroxide as a phosphor binder.

An 18-month-old boy affected with congenital nephrotic syndrome, who was under medical therapy with enalapril as an antiproteinuric agent and nutritional supplements, was controlled up to age of one; he presented with CRF in 18 ^th month of age and needed renal replacement therapy because of refractory acidosis (pH 7.03, Base: 6 meq/L), hyperphosphatemia (17 mg/dl), and severe hypocalcemia (5 mg/dl). Hyperphosphatemia, in this case, obligated us using aluminum hydroxide to remove phosphor which led to severe symptomatic convulsion due to hypocalcemia. We initiate aluminum hydroxide therapy (at a dose of 150 mg/kg/daily in four divided doses) and chronic peritoneal dialysis catheter insertion simultaneously. After 4 days, episodes of tics reported by mother in head and neck progressed to persistent head tremor at 5 ^th day with decreased cognition (indifference to environmental stimuli and his mother's face) with nonsense speech [Video 1]. At first step, we held onto aluminum hydroxide and continued peritoneal dialysis. His electroencephalograph (EEG) shows abnormal sleep pattern (sleep spindle has not formed) and brain imaging was unremarkable in spite of his developmental delay. His serum aluminum level was not accessible. After discharge (3 days later), his tremor resolved a bit and his face was not masked but he was agitated with noise and trigger; gradually, he could recognize his parents as prior to the usage of aluminum by the end of first month, as reported by his mother.

Aluminum toxicity occurs in patients with Glomerular filtration rate (GFR) <30 ml/min/1.73 m² . In these patients, aluminum absorption may occur from the gut, the dialysate fluid, or from parenteral infusions which are inadequately excreted in kidney failure. ^[12] Long-term use of aluminum phosphate binders as aluminum contaminated dialysate can result in progressive encephalopathy with symptoms of agitation, speech disorder, confusion, myoclonus, coma, and/or seizures, ^[8] while aluminum level is not a sensitive test for detecting or predicting aluminum toxicity in these patients. ^[13],[14]

Children, who developed chronic renal insufficiency before the age of one and who are not under renal replacement therapy, can develop a progressive encephalopathy with a clinical picture similar to dialysis dementia characterized by developmental delay, the evolution of microcephaly, seizures, hypotonia, and involuntary movements, including chorea and tremor, ^[15],[16] whereas acute toxicity by aluminum is a rare event especially in children. ^[17] In adult with kidney disease, aluminum acute toxicity can be symptomatic 10 days after aluminum usage with confusion, deliriium, tremors, hallucinations, slurred speech, and dis-orientation and symptoms were reversible in 60 days. ^[11]

Our case showed signs of aluminum neurotoxicity soon after 5 days following use of aluminum hydroxide (150 mg/kg/d) although his complaints started on 4 ^th day with head tics and grimace. These complaints progressed to full blown picture with symptoms of declining of cognition (unresponsive to mother face and voice), head tremor, incoherent speech progressing to speechless state which resolved after discontinuation of drug and continuous dialysis over 1 month. This case shows that young children with CRF and preexisting developing retardation, acidosis, and hyperparathyroidism are so prone to developing acute encephalopathy as soon as 5 days following ingestion of aluminum hydroxide (150 mg/kg/daily). The early complaints may be so subtle like as tics and grimace can be recognized only by parents. It progresses rapidly to persistent head tremor, speech arrest, and incognition that obviate aluminum usage in young children with CRF.

Brain imaging is not diagnostic and EEG shows nonspecific findings. The main key to the diagnosis is clinical findings and the parents' report about baby's complaints.

This case shows for the first time that without measuring aluminum serum level, aluminum cannot be a safe drug for children who are affected with CRF even for 5 days usage. Aluminum can cause head tremor, incognesia, and speech arrest in children affected with CRF shortly (before 5 days) after usage, a reversible event, that abates slowly over 1 month after holding it.

 

References

1.	Alfrey AC. Aluminium and renal disease. In: Bourke E, Mallick NP, Pollak VE, editor. Moving points in nephrology. Contrib Nephrol 1993; 102:110-24.
2.	Trapp GA. Interactions of aluminum with cofactors, enzymes, and other proteins. Kidney Int Suppl 1986;18:S12-6.
3.	Rivera-Vazquez AB, Noriega-Sanchez A, Ramirez-Gonzalez R, Martinez-Maldonado M. Acute hypercalcemia in hemodialysis patients: Distinction from dialysis dementia. Nephron 1980;25:243-6.
4.	Nakamura H, Rose PG, Blumer JL, Reed MD. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. J Clin Pharmacol 2000;40:296-300.
5.	Alfrey AC. Aluminum intoxication. N Engl J Med 1984;310:1113-5.
6.	Alfrey AC. Aluminum metabolism and toxicity in uremia. J UOEH 1987;9 Suppl:123-32.
7.	Alfrey AC, Hegg A, Craswell P. Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 1980;33:1509-16.
8.	Rob PM, Niederstadt C, Reusche E. Dementia in patients undergoing long-term dialysis: Aetiology, differential diagnoses, epidemiology and management. CNS Drugs 2001;15:691-9.
9.	Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976;294:184-8.
10.	Simoes J, Barata JD, D'Haese PC, De Broe ME. Cela n'arrive qu'aux autres (aluminium intoxication only happens in the other nephrologist's dialysis centre). Nephrol Dial Transplant 1994;9:67-8.
11.	Egbuna OI, Bose A. Acute aluminum neurotoxicity secondary to treatment of severe hyperphosphatemia of acute renal failure and the k/doqi guidelines: A case report and review of the literature. Internet J Nephrol 2005;2:2.
12.	Alfrey AC. Aluminum metabolism. Kidney Int 1986;18:8-11.
13.	Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis 2005;46:316-9.
14.	Chazan JA, Abuelo JG, Blonsky SL. Plasma aluminum levels (unstimulated and stimulated): Clinical and biochemical findings in 185 patients undergoing chronic hemodialysis for 4 to 95 months. Am J Kidney Dis 1989;13:284-9.
15.	Rotundo A, Nevins TE, Lipton M, Lockman LA, Mauer SM, Michael AF. Progressive encephalopathy in children with chronic renal insufficiency in infancy. Kidney Int 1982;21:486-91.
16.	Trompeter RS, Polinsky MS, Andreoli SA, Fennell RS. Neurologic complications of renal failure. Am J Kidney Dis 1986;7:318-28.
17.	Andrasi E, Pali N, Molnar Z, Kosel S. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 2005;7:273-84.

This article has been cited by 1 Unravelling the molecular mechanism of mutagenic factors impacting human health Keshav Goyal, Harsh Goel, Pritika Baranwal, Aman Dixit, Fahad Khan, Niraj Kumar Jha, Kavindra Kumar Kesari, Pratibha Pandey, Avanish Pandey, Mercilena Benjamin, Ankit Maurya, Vandana Yadav, Rana Suryauday Sinh, Pranay Tanwar, Tarun Kumar Upadhyay, Sandeep Mittan Environmental Science and Pollution Research. 2021; [Pubmed] | [DOI] 2 Elevated IgG Antibody to Aluminum Bound to Human Serum Albumin in Patients with Crohn’s, Celiac and Alzheimer’s Disease Aristo Vojdani Toxics. 2021; 9(9): 212 [Pubmed] | [DOI] 3 Acute aluminum chloride toxicity revisited: Study on DNA damage and histopathological, biochemical and neurochemical alterations in rat brain Laraib Liaquat, Sadia Sadir, Zehra Batool, Saiqa Tabassum, Sidrah Shahzad, Asia Afzal, Saida Haider Life Sciences. 2019; 217: 202 [Pubmed] | [DOI] 4 Serum aluminum levels in dialysis patients after sclerotherapy of internal hemorrhoids with aluminum potassium sulfate and tannic acid Akira Tsunoda,Masafumi Nakagi,Nobuyasu Kano,Masahiko Mizutani,Kenji Yamaguchi Surgery Today. 2014; [Pubmed] | [DOI] 5 Aluminium hydroxide Reactions Weekly. 2013; 1465(1): 6 [Pubmed] | [DOI]